Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IKT Stock Forecast 2025-2026
$1.50
Current Price
$181.90M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to IKT Price Targets
+433.3%
To High Target of $8.00
+433.3%
To Median Target of $8.00
+233.3%
To Low Target of $5.00
IKT Price Momentum
-1.3%
1 Week Change
0.0%
1 Month Change
-54.3%
1 Year Change
-53.8%
Year-to-Date Change
-64.3%
From 52W High of $4.20
+12.8%
From 52W Low of $1.33
📊 TOP ANALYST CALLS
Did IKT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Inhibikase is one of their latest high-conviction picks.
Latest IKT Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, IKT has a bullish consensus with a median price target of $8.00 (ranging from $5.00 to $8.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $1.50, the median forecast implies a 433.3% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Dennis Ding at Jefferies, projecting a 433.3% upside. Conversely, the most conservative target is provided by Edward White at HC Wainwright & Co., suggesting a 233.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IKT Analyst Ratings
3
Buy
0
Hold
0
Sell
IKT Price Target Range
Low
$5.00
Average
$8.00
High
$8.00
Current: $1.50
Latest IKT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IKT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 28, 2025 | HC Wainwright & Co. | Edward White | Neutral | Reiterates | $N/A |
| Feb 12, 2025 | HC Wainwright & Co. | Edward White | Neutral | Downgrade | $N/A |
| Nov 8, 2024 | Jefferies | Dennis Ding | Buy | Initiates | $8.00 |
| Oct 14, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $5.00 |
| Aug 16, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $15.00 |
| May 21, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $23.00 |
| Mar 7, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $27.00 |
| Mar 5, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $27.00 |
| Aug 15, 2023 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $27.00 |
| Jun 30, 2023 | HC Wainwright & Co. | Edward White | Buy | Maintains | $27.00 |
| Jun 22, 2023 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $5.00 |
| Apr 18, 2023 | HC Wainwright & Co. | Edward White | Buy | Initiates | $5.00 |
| Nov 16, 2022 | JonesTrading | Soumit Roy | Hold | Downgrade | $N/A |
| Jul 15, 2021 | JonesTrading | Soumit Roy | Buy | Initiates | $12.00 |
Inhibikase Therapeutics Inc. (IKT) Competitors
The following stocks are similar to Inhibikase based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Inhibikase Therapeutics Inc. (IKT) Financial Data
Inhibikase Therapeutics Inc. has a market capitalization of $181.90M with a P/E ratio of 3.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -131.7%.
Valuation Metrics
Market Cap
$181.90M
Enterprise Value
$35.44M
P/E Ratio
3.2x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+68.6%
Current Ratio
11.7x
Debt/Equity
0.0x
ROE
-131.7%
ROA
-79.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Inhibikase Therapeutics Inc. (IKT) Business Model
About Inhibikase Therapeutics Inc.
What They Do
Develops therapeutics for neurodegenerative diseases.
Business Model
The company generates revenue by developing and commercializing innovative drugs targeting neurodegenerative and infectious diseases. It utilizes a proprietary platform to create therapies that interrupt harmful biological pathways, particularly focusing on conditions like Parkinson’s disease.
Additional Information
Inhibikase Therapeutics is positioned strongly within the biopharmaceutical sector, focusing on advanced research and development to address unmet medical needs. Their work aims to provide new treatment options for debilitating neurological conditions, contributing to significant advancements in medical science.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
15
CEO
Mr. Mark T. Iwicki
Country
United States
IPO Year
2020
Website
www.inhibikase.comInhibikase Therapeutics Inc. (IKT) Latest News & Analysis
Latest News
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
16 days ago
Quick Summary
Inhibikase Therapeutics plans to initiate a Phase 3 clinical study for IKT-001 in Pulmonary Arterial Hypertension in Q1 2026, potentially accelerating FDA approval by about three years.
Why It Matters
Inhibikase's Phase 3 study for IKT-001 could expedite FDA approval for PAH treatments, potentially increasing the company's market value and attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
16 days ago
Quick Summary
Inhibikase Therapeutics (NASDAQ: IKT) has launched an underwritten public offering of common stock and pre-funded warrants. The underwriters may purchase an additional 15% of shares. Completion is subject to market conditions.
Why It Matters
Inhibikase's public offering signals potential dilution of existing shares, impacting stock value. It also reflects the company's need for capital to advance its PAH treatment development.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Inhibikase Therapeutics (NASDAQ: IKT) announced a public offering of 46.1 million shares at $1.45 each and pre-funded warrants at $1.449, aiming for $100 million gross proceeds, closing on November 24, 2025.
Why It Matters
Inhibikase's $100 million stock offering signals potential dilution for existing shareholders but provides crucial funding for its PAH drug development, influencing future growth and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
22 days ago
Quick Summary
Inhibikase Therapeutics (Nasdaq: IKT) reported Q3 2025 financial results, focusing on advancing IKT-001 toward late-stage trials for Pulmonary Arterial Hypertension.
Why It Matters
Inhibikase's advancement towards late-stage trials for IKT-001 in treating PAH signals potential for significant market impact and revenue, influencing investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Inhibikase Therapeutics appointed Timothy Pigot as Chief Commercial and Strategy Officer, enhancing leadership in developing treatments for pulmonary arterial hypertension (PAH).
Why It Matters
The appointment of Timothy Pigot as Chief Commercial and Strategy Officer enhances Inhibikase's leadership in the PAH market, potentially impacting its strategic direction and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
3 months ago
Quick Summary
Inhibikase Therapeutics (Nasdaq: IKT) reported Q2 2025 financial results and recent advancements in therapies for cardiopulmonary diseases, including Pulmonary Arterial Hypertension (PAH).
Why It Matters
Inhibikase's financial results and developments in PAH treatments can influence stock performance, signaling potential growth or risk in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About IKT Stock
What is Inhibikase Therapeutics Inc.'s (IKT) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Inhibikase Therapeutics Inc. (IKT) has a median price target of $8.00. The highest price target is $8.00 and the lowest is $5.00.
Is IKT stock a good investment in 2026?
According to current analyst ratings, IKT has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.50. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IKT stock?
Wall Street analysts predict IKT stock could reach $8.00 in the next 12 months. This represents a 433.3% increase from the current price of $1.50. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Inhibikase Therapeutics Inc.'s business model?
The company generates revenue by developing and commercializing innovative drugs targeting neurodegenerative and infectious diseases. It utilizes a proprietary platform to create therapies that interrupt harmful biological pathways, particularly focusing on conditions like Parkinson’s disease.
What is the highest forecasted price for IKT Inhibikase Therapeutics Inc.?
The highest price target for IKT is $8.00 from Dennis Ding at Jefferies, which represents a 433.3% increase from the current price of $1.50.
What is the lowest forecasted price for IKT Inhibikase Therapeutics Inc.?
The lowest price target for IKT is $5.00 from Edward White at HC Wainwright & Co., which represents a 233.3% increase from the current price of $1.50.
What is the overall IKT consensus from analysts for Inhibikase Therapeutics Inc.?
The overall analyst consensus for IKT is bullish. Out of 3 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are IKT stock price projections?
Stock price projections, including those for Inhibikase Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 12:36 AM UTC